Compare · RMD vs SIBN
RMD vs SIBN
Side-by-side comparison of ResMed Inc. (RMD) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 38.2x SIBN ($892.3M).
- RMD has been more active in the news (9 items in the past 4 weeks vs 6 for SIBN).
- RMD has more recent analyst coverage (25 ratings vs 12 for SIBN).
- Company
- ResMed Inc.
- SI-BONE Inc.
- Price
- -
- -
- Market cap
- $34.07B
- $892.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 12
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target
Latest SIBN
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 144 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Director Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $378,160 worth of shares (20,000 units at $18.91) as part of a pre-agreed trading plan (SEC Form 4)
- SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
- Chief Executive Officer Francis Laura sold $522,596 worth of shares (25,972 units at $20.12) as part of a pre-agreed trading plan (SEC Form 4)